#hemodynamic
New publication by Concordia SOH researchers: "Hemodynamic spectral signatures across vigilance states: a whole-night EEG/fNIRS investigation"

academic.oup.com/sleep/advanc...
Hemodynamic spectral signatures across vigilance states: a whole-night EEG/fNIRS investigation
Sleep is a dynamic process, involving fluctuation of neuronal, hemodynamic and metabolic cerebral activities. However, sleep hemodynamics are incompletely
academic.oup.com
November 16, 2026 at 3:57 PM
Cardiogenic Shock: From Hemodynamic Collapse to a Precision-Medicine-Driven FutureT

CCR Journal Watch
https://criticalcarereviews.com/latest-evidence/journal-watch
November 15, 2026 at 7:40 PM
Semaglutide slashes cardiac congestion in heart failure with preserved ejection fraction, prompting hemodynamic remission in over half of patients.

by Borlaug BA, Jensen MD (...) Carter RE et 5 al. in Nat Med #MedSky

👉 get more here

📖 read the article:
Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial - Nature Medicine
As presented at the 2026 American Heart Association Scientific Sessions, in a placebo-controlled randomized clinical trial, semaglutide significantly improved pulmonary artery wedge pressure and other hemodynamic parameters during low-intensity exercise in individuals with heart failure with preserved ejection fraction and obesity.
www.nature.com
November 17, 2026 at 11:47 AM
Today's Paper of the Day is:

Understanding Hemodynamic Incoherence: Mechanisms, Phenotypes, and Implications for Treatment

https://criticalcarereviews.com/latest-evidence/paper-of-the-day

Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2026
November 17, 2026 at 8:41 AM
Open Access UCL Research: ESICM guidelines on circulatory shock and hemodynamic monitoring 2025 discovery.ucl.ac.uk/id/eprint/10...
ESICM guidelines on circulatory shock and hemodynamic monitoring 2025 - UCL Discovery
UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
discovery.ucl.ac.uk
November 16, 2026 at 1:59 PM
元論文→ Reference: The aging human brain exhibits reduced hemodynamic and cerebrospinal fluid flow waves during sleep. Nat Aging. 2026. doi: 10.1038/s43587-026-01270-4

www.nature.com/articles/s43...
The aging human brain exhibits reduced hemodynamic and cerebrospinal fluid flow waves during sleep - Nature Aging
This work shows that cerebrospinal fluid flow during sleep is impaired in the aging human brain, before the onset of any neurological disorder, and identifies parallel neural and cerebrovascular mecha...
www.nature.com
November 18, 2026 at 12:14 AM
#ECMO feasible strategy in life-threatening pulmonary hemorrhage! Acceptable outcomes can be achieved in selected pts with refractory hypoxemia/hemodynamic collapse: survival & complications comparable to overall @theelso.bsky.social Registry #ECLS cohort @asaiojournal.bsky.social
🖇️ bit.ly/48ov4Co
#ECMO support as bridge to decision/intervention in patients with pulmonary hemorrhage
🔎 ELSO Registry study; 96 pts 2003-23
⚠️ complications occurred in 54%, mainly #AKI with need for RRT, bleeding, respiratory tract infections
🩺 ECMO weaning 49%, survival to discharge 48%
🖇️ bit.ly/48ov4Co
November 17, 2026 at 8:41 PM
An MIT study found that older adults have significantly weaker cerebrospinal fluid waves during sleep, which may impair the brain’s waste-clearing processes. The decline is tied to reduced deep-sleep brain waves and vascular changes, not just shorter sleep duration.

#research #space #science
The aging human brain exhibits reduced hemodynamic and cerebrospinal fluid flow waves during sleep -
This work shows that cerebrospinal fluid flow during sleep is impaired in the aging human brain, before the onset of any neurological disorder, and identifies parallel neural and c
www.nature.com
November 17, 2026 at 2:13 PM
The aging human brain exhibits reduced hemodynamic and cerebrospinal fluid flow waves during sleep
Circulation of CSF during sleep is regulated by a complex neurovascular cascade in which neural slow wave events elicit high-amplitude, low-frequency vascular pulsations that result in large-scale changes in blood volume12,17, due to local neurovascular coupling, autonomic effects and neuromodulatory rhythms13,50. These large hemodynamic waves then mechanically drive CSF into and out of the brain via volume displacement (Fig. 1a). To test how this pathway is altered in aging, we collected simultaneous EEG and fast-fMRI data during nighttime sleep in a group of young (18–39 years, n = 31) and older (60–84 years, n = 41) adults. We used an accelerated fMRI protocol that enabled measurement of CSF flow, and positioned the imaging volume so the bottom edge of the volume intersected with the fourth ventricle (Fig. 1b). This imaging method leverages the concept of flow-related enhancement12,49,51, in which fluid that flows into the imaging volume is bright as it enters and moves into the volume, to detect changes in CSF flow velocity (Methods). This technique enabled simultaneous measurement of hemodynamics (in gray matter) and CSF inflow (in the fourth ventricle) through distinct contrast mechanisms (BOLD versus inflow signals; see ref. 49). During the scans, participants were instructed to rest...
www.nature.com
November 14, 2026 at 1:29 AM
2/3 Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial.

Nat Med · 8 Nov 2026
doi.org/10.1038/s41591-026-04762-3
November 12, 2026 at 4:46 PM
From the latest issue: Nohara and colleagues show that hemodynamic failure after EVT occurs in over half of patients with CLTI and is associated with delayed wound healing, reintervention, and wound recurrence.
doi.org/10.1177/1358...
November 12, 2026 at 3:31 PM
🫀 What comes after optimal GDMT in HF?

Device-based therapies can address residual symptoms & risk:
⚡ CRT & contractility modulation
🫀 Valve interventions
📡 Hemodynamic monitoring
🔋 Baroreflex activation
Yet many remain underused. 💜

🔗 bit.ly/4z6KUNt
November 12, 2026 at 7:30 PM
Whole-brain modeling of dynamic causal circuits in human cognition using amortized ...
Understanding dynamic mechanisms underlying cognition remains a major challenge in human neuroscience. Here, we develop, validate, and apply Multivariate Dynamical Systems Identification with Amortized Variational Inference (MDSI-AVI), a computational framework designed to address critical challenges in capturing asymmetric, context-dependent, whole-brain directed interactions while accounting for regional hemodynamic response variability in fMRI data. MDSI-AVI leverages simulation-based inference through forward and reverse variational inference to address the limitations of conventional variational methods in high-dimensional settings. By averaging over uncertainty in hemodynamic response parameters using forward simulation, MDSI-AVI provides well-calibrated posteriors of directed connectivity that scale efficiently to networks with hundreds of nodes. Applied to Human Connectome Project data (N = 728), MDSI-AVI provides insights into working memory mechanisms, identifying the dorsal anterior insula as a critical hub influencing activity at the whole-brain level. We demonstrate task-dependent modulation of causal influences, where the salience network drives frontoparietal network activity, which differentially influences the default mode and sensorimotor networks depending on working memory load. These whole-brain causal interactions distinguish task conditions with high accuracy and predict working memory performance. Our framework demonstrates reproducible results across whole-brain parcellations, establishing MDSI-AVI as a robust tool for advancing our understanding of circuit dynamics in cognition and disease...
www.nature.com
November 18, 2026 at 10:56 AM
Useful in the awake pt who you don't think will tolerate a neck line.

emcrit.org/pulmcrit/hem...
Hemodynamic access for the crashing patient: The dirty double
0 0 Introduction with a case 0 A 75-year-old man presents in transfer to the ICU for management of bradycardia and hyperkalemia.  His history is notable
emcrit.org
November 11, 2026 at 9:45 PM
JMIR Res Protocols: Renin Kinetics and Hemodynamic Response During Treatment of Vasoplegic Shock With Angiotensin II (TENSINTEST): #Protocol for a Multicenter Observational #Study
Renin Kinetics and Hemodynamic Response During Treatment of Vasoplegic Shock With Angiotensin II (TENSINTEST): #Protocol for a Multicenter Observational #Study
Background: Shock is a life-threatening condition that can lead to multiorgan failure and death. Vasopressors are needed for the treatment of vasoplegic (distributive) shock. Angiotensin II (AT II) is a novel vasopressor. Approximately two-thirds of patients respond to AT II, and one-third do not. AT II is part of the renin-angiotensin-aldosterone system (RAAS). Renin is the limiting enzyme of the RAAS, and among other mechanisms, its concentration is regulated by AT II concentration through a negative feedback loop. It might be an indicator of response to AT II therapy. Objective: We designed a #Study with a primary objective of developing and standardizing an AT II stress test, which could help predict the responsiveness to AT II in patients with distributive shock, regardless of its origin. Methods: This is an investigator-initiated, multicenter observational clinical #Study of renin kinetics before and 6 hours after starting an infusion of AT II in patients with vasoplegic shock and adequate fluid resuscitation who are severely ill. Prior to AT II, patients will receive an infusion of norepinephrine base of 0.3 mcg per kilogram per minute or higher, and vasopressin of 0.03 IU per minute according to institutional #Protocol. Blood samples for serum renin determination will be obtained immediately prior to and after 6 hours of AT II infusion. We hypothesize that patients who demonstrate a negative trend in relative renin ratio (defined as renin plasma concentration at baseline or at 6 hours after treatment with AT II divided by upper normal concentration of plasma renin [50 mU/L]) will have a greater number of 28-day organ failure–free days (days without vasopressors, mechanical ventilation, or renal replacement therapy). The primary analysis will assess the association between early renin reduction and organ failure–free days using an adjusted proportional odds ordinal regression model. Results: The #Research was funded in December 2024. After obtaining ethics approval in July 2025, data collection started on August 1, 2025. As of July 2026, a total of 70 patients had been enrolled. Data collection is expected to be completed in 2027, after which the results will be analyzed and published. Conclusions: The goal of our #Study is to determine whether renin 0-6 h kinetics (difference between renin levels before and 6 hours after starting an AT II infusion) are associated with clinical outcomes in patients who require AT II. Our #Study could contribute to the development of a more individualized approach to vasopressor therapy and avoidance of inappropriate use of AT II in patients who are not responders, allowing earlier discontinuation of AT II and consideration of alternative therapies. Trial Registration: ClinicalTrials.gov NCT06539234; https://clinicaltrials.gov/#Study/NCT06539234 International Registered Report Identifier (IRRID): DERR1-10.2196/102437
dlvr.it
November 9, 2026 at 7:31 PM
Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial
The glucagon-like peptide-1 receptor agonist semaglutide improves symptoms in heart failure with preserved ejection fraction (HFpEF) through unclear mechanisms. Here, in this double-blind, placebo-controlled trial, we randomly assigned 81 patients (47 women) with HFpEF and obesity to semaglutide (2.4 mg weekly) or placebo for 52 weeks. The primary outcome was the change in invasively measured pulmonary artery wedge pressure (PAWP), a direct measure of cardiac congestion, during low-intensity exercise. Additional mechanistic outcomes included other hemodynamic measures and hemodynamic HFpEF remission (defined as normal PAWP under conditions of both rest and exercise at 52 weeks). At baseline, PAWP was 17.5 ± 4.3 mmHg at rest and 31.7 ± 5.2 mmHg during exercise. After 52 weeks, the mean change in PAWP during exercise was −9.8 (95% confidence interval (CI): −11.3 to −8.2) mmHg with semaglutide and +0.9 (95% CI: −1.3 to 3.0) mmHg with placebo (estimated difference, −10.6 mmHg; 95% CI: −13.3 to −8.0; P < 0.0001). As compared to placebo, semaglutide also decreased resting PAWP (estimated difference, −7.1 mmHg; 95% CI: −9.8 to −4.4; P < 0.0001), and semaglutide-treated patients were more likely to experience hemodynamic remission (53.7% versus 7.4%, odds ratio = 14.1, 95% CI: 3.0−134.6, P < 0.001). The...
www.nature.com
November 8, 2026 at 5:11 PM
Effects of semaglutide on cardiac structure and function in heart failure with preserved ...
Glucagon-like peptide-1 receptor agonists improve symptoms in patients with obesity and heart failure with preserved ejection fraction (HFpEF). We recently demonstrated that semaglutide reduces exertional pulmonary artery wedge pressure (PAWP) in obesity-related HFpEF, but potential effects of semaglutide on cardiac structure and function that may underlie these hemodynamic improvements remain unclear. In this prespecified cardiovascular magnetic resonance (CMR) substudy of the randomized CAMEO-SEMA trial, 49 participants (33 semaglutide, 16 placebo, 28 female) underwent CMR at baseline and 52 weeks, within 1 day of invasive exercise hemodynamic assessment. The prespecified primary CMR endpoint was change in left atrial (LA) reservoir strain; other prespecified CMR endpoints included LV filling dynamics, which were assessed by early filling rate indexed to end-diastolic volume (eFR/EDV). Compared with placebo, semaglutide improved LA reservoir strain (+5.7% [95% CI, +0.3 to +9.7]; P=0.037) and eFR/EDV (+0.64 s−1 [95% CI, +0.42 to +1.00]; P<0.0001). Improvements in LA reservoir strain and LV filling dynamics were associated with reductions in exercise PAWP (r=−0.46, P<0.001 and r=−0.65, P<0.0001, respectively). With respect to other prespecified CMR endpoints, semaglutide reduced LV mass, restored more physiologic LV geometry, and improved right ventricular function and biventricular myocardial mechanics. The results of this CMR substudy indicate that...
www.nature.com
November 9, 2026 at 5:37 PM
These are patients who are acutely ill, with signs of acute right heart strain. They are on LMWH or unfractioned heparin. Original hypothesis was that it could avoid hemodynamic deterioration.
Whether it is worthwhile later on is another qeuestion.
November 5, 2026 at 6:17 PM
This review details key PE risk factors and uses hemodynamic stability-based categorization to aim for precise risk stratification with established diagnostic tools and scoring systems 🫁📋 #PulmonaryEmbolism #RiskStratification
mdpi.com/2227-9059/12...
November 6, 2026 at 12:33 AM
New in JMIR mhealth: Association Between Intradialytic Foot Temperature Gradients and Severe Peripheral Artery Disease in Patients Undergoing Hemodialysis: Prospective Cohort Study
Association Between Intradialytic Foot Temperature Gradients and Severe Peripheral Artery Disease in Patients Undergoing Hemodialysis: Prospective Cohort Study
Background: Peripheral artery disease (PAD) is prevalent in hemodialysis (HD) patients but remains difficult to diagnose due to unreliable ankle-brachial index (ABI) measurements caused by vascular calcification. We hypothesized that monitoring foot temperatures and their changes during HD, provoked by hemodynamic shifts, could serve as a novel diagnostic tool for detecting severe PAD. Objective: This study aims to evaluate the diagnostic utility of intradialytic foot temperature monitoring using #Wearable #Mobile #Health (#mHealth) sensors for detecting severe PAD in patients undergoing HD. Methods: In this prospective observational study, we recruited 109 patients undergoing chronic maintenance HD. Skin temperatures were monitored continuously at the instep and sole during HD sessions using #Wearable sensors (Temp Pal, iWEECARE Co, Ltd), which are wireless, nanochip-based #mHealth thermometers with ±0.05 °C accuracy. The diagnostic performance of temperature parameters, specifically the temperature difference between the wrist and foot at the end of HD, was evaluated against vascular duplex ultrasound (DUS). Severe PAD was defined as abnormal (monophasic or absent) flow in the distal posterior tibial artery (PTA) or anterior tibial artery (ATA). Results: Patients with abnormal tibial flow on DUS exhibited significantly different temperature gradients between the wrist and foot at the end of dialysis compared to those with normal flow. Receiver operating characteristic (ROC) analysis demonstrated that the wrist-foot temperature difference at the sole effectively discriminated abnormal ATA flow (area under the curve [AUC] 64.5%, 95% CI 57.8%‐70.9%) and abnormal PTA flow (AUC 62.0%, 95% CI 55.2%‐68.5%). Notably, an instep wrist-foot temperature difference cutoff of –2.2 °C or less yielded a specificity of 97.6% (95% CI 94.0%-99.3%) for detecting abnormal PTA flow. Conclusions: Intradialytic foot temperature monitoring, particularly the temperature gradient between the wrist and foot, significantly correlates with severe tibial artery flow abnormalities. This method offers an accessible, noninvasive screening adjunct to the ABI for detecting severe PAD in the HD population. These findings indicate an association rather than a standalone diagnostic test; given the modest discriminative ability, external validation is warranted.
dlvr.it
November 6, 2026 at 10:21 PM
Function | New Article Alert! 🚨 A diameter and hemodynamic regulation model utilizing an #arteriolar network structural model and experiment-based machine learning. Read the article: https://ow.ly/EFn95102qPH #machineLearning
November 4, 2026 at 2:30 PM